Nicholas M Czosnyka1, F Paul Buckley2, Stephanie L Doggett2, Hannah Vassaur2, Erin E Connolly3, Andrew J Borgert4, Kara J Kallies4, Shanu N Kothari5. 1. General Surgery Residency, Department of Medical Education, Gundersen Medical Foundation, La Crosse, WI, USA. 2. The Heartburn & Acid Reflux Center, Baylor Scott & White Healthcare, Round Rock, TX, USA. 3. Department of General and Vascular Surgery, Gundersen Health System, La Crosse, WI, USA. 4. Department of Research, Gundersen Medical Foundation, La Crosse, WI, USA. 5. Department of General and Vascular Surgery, Gundersen Health System, La Crosse, WI, USA. Electronic address: snkothar@gundersenhealth.org.
Abstract
BACKGROUND: Magnetic sphincter augmentation (MSA) is FDA approved for the surgical treatment of GERD. While multiple reports from academic settings exist, we report the early experience from two community-based health systems. METHODS: The first 102 post-trial cases of MSA were reviewed. Outcomes were compared to those in the initial clinical trial. RESULTS: Mean follow-up duration was 7.6 months. GERD medication use decreased from 98% preoperative to 8% postoperative (P<0.001). Median GERD health-related quality of life (HRQL) improved from 27 preoperative to 5 postoperative (P<0.001). Patient satisfaction increased from 8% preoperative to 84% postoperative (P<0.001). Results were similar to the trial data. CONCLUSIONS: MSA is a safe and effective treatment for GERD, with significant improvement in quality of life. GERD-HRQL, medication reduction, operative times, and dysphagia rates were similar to other reports, demonstrating the reproducibility of MSA. Lower dilation rates may be due to refinements in technique and postoperative dietary management.
BACKGROUND: Magnetic sphincter augmentation (MSA) is FDA approved for the surgical treatment of GERD. While multiple reports from academic settings exist, we report the early experience from two community-based health systems. METHODS: The first 102 post-trial cases of MSA were reviewed. Outcomes were compared to those in the initial clinical trial. RESULTS: Mean follow-up duration was 7.6 months. GERD medication use decreased from 98% preoperative to 8% postoperative (P<0.001). Median GERD health-related quality of life (HRQL) improved from 27 preoperative to 5 postoperative (P<0.001). Patient satisfaction increased from 8% preoperative to 84% postoperative (P<0.001). Results were similar to the trial data. CONCLUSIONS: MSA is a safe and effective treatment for GERD, with significant improvement in quality of life. GERD-HRQL, medication reduction, operative times, and dysphagia rates were similar to other reports, demonstrating the reproducibility of MSA. Lower dilation rates may be due to refinements in technique and postoperative dietary management.
Authors: Saurabh Chandan; Babu P Mohan; Shahab R Khan; Lokesh K Jha; Amaninder J Dhaliwal; Mohammad Bilal; Muhammad Aziz; Andrew Canakis; Sumant Arora; Sarah Malik; Lena L Kassab; Suresh Ponnada; Ishfaq Bhat; Alexander T Hewlett; Neil Sharma; Stephanie McDonough; Douglas G Adler Journal: Endosc Int Open Date: 2021-04-13
Authors: Katrin Schwameis; Milena Nikolic; Deivis G Morales Castellano; Ariane Steindl; Sarah Macheck; M Riegler; Ivan Kristo; Barbara Zörner; Sebastian F Schoppmann Journal: Sci Rep Date: 2018-05-09 Impact factor: 4.379
Authors: Katrin Schwameis; Milena Nikolic; Deivis G Morales Castellano; Ariane Steindl; Sarah Macheck; Ivan Kristo; Barbara Zörner; Sebastian F Schoppmann Journal: World J Surg Date: 2018-10 Impact factor: 3.352